

Correction: A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer



In this article (Clin Cancer Res 2017;23:935–45), which was published in the February 15, 2017, issue of *Clinical Cancer Research* (1), the corresponding author alerted us to errors in Table 2. Specifically, the median DHEAS for patients with an abiraterone level >35 ng/mL was incorrectly listed as 645 ng/dL. The correct median should be 435 ng/dL with IQR (130–525). The median DHT for patients with an abiraterone level ≤35 ng/mL was also incorrectly listed as 1.3 ng/dL. The correct median should be 1.0 ng/dL. The conclusions put forth in the article remain unchanged. The corrected version of Table 2 is below. The authors regret this error.

Table 2. Association of abiraterone and hormone levels at cycle 3

| | Abiraterone ≤ 35 ng/mL | | Abiraterone > 35 ng/mL | | All patients | | P |
|------------------------|------------------------|-------------------|------------------------|----------------|--------------|-----------------|------|
| | n | Median (q1–q3) | n | Median (q1–q3) | n | Median (q1–q3) | |
| Pregnenolone, ng/dL | 13 | 374 (268–584) | 13 | 588 (418–929) | 26 | 516 (312–879) | 0.05 |
| Progesterone, ng/dL | 13 | 87 (51–163) | 13 | 141 (112–298) | 26 | 124 (70–217) | 0.09 |
| DHEAS, ng/dL | 13 | 1,095 (380–1,300) | 13 | 435 (130–525) | 26 | 505 (170–1,140) | 0.06 |
| DHEA, ng/dL | 13 | 1.9 (1.8–2.7) | 13 | 2.4 (1.7–2.9) | 26 | 2.1 (1.8–2.9) | 0.90 |
| Androstenedione, ng/dL | 13 | 0.5 (0.3–0.5) | 13 | 0.5 (0.4–0.6) | 26 | 0.5 (0.3–0.6) | 0.35 |
| Testosterone, ng/dL | 13 | 0.4 (0.3–0.7) | 13 | 0.5 (0.3–0.6) | 26 | 0.5 (0.3–0.6) | 0.74 |
| DHT, ng/dL | 13 | 1.0 (1.0–1.0) | 13 | 1.0 (1.0–1.0) | 26 | 1.0 (1.0–1.0) | — |

Reference

- McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, et al. A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer. Clin Cancer Res 2017;23:935–45.

Published online July 14, 2017.

doi: 10.1158/1078-0432.CCR-17-0975

©2017 American Association for Cancer Research.

Clinical Cancer Research

Correction: A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer

Clin Cancer Res 2017;23:3970.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/23/14/3970>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/23/14/3970.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/14/3970>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.